Primary endpoint missed, but other outcomes point to overall benefit
PHILADELPHIA – A novel treatment designed to allow teenagers who survived so-called Fontan heart reconstruction surgery as babies to have better exercise function failed to achieve its primary endpoint in a large placebo-controlled trial reported here.